Long term administration of tocilizumab improves renal amyloid A (AA) amyloidosis deposition in Familial Mediterranean fever

Keita InuiNephrology Center, Toranomon Hospital, Tokyo, Japan;

Naoki SawaNephrology Center, Toranomon Hospital, Tokyo, Japan;

Tatsuya SuwabeNephrology Center, Toranomon Hospital, Tokyo, Japan;

Hiroki MizunoNephrology Center, Toranomon Hospital, Tokyo, Japan;

Masayuki YamanouchiNephrology Center, Toranomon Hospital, Tokyo, Japan;

Rikako HiramatsuNephrology Center, Toranomon Hospital, Tokyo, Japan;

Noriko HayamiNephrology Center, Toranomon Hospital, Tokyo, Japan;

Junichi HoshinoNephrology Center, Toranomon Hospital, Tokyo, Japan; ;Okinaka Memorial Institute for Medical Research, Tokyo, Japan;

Keiichi KinowakiDepartment of Pathology, Toranomon Hospital, Tokyo, Japan

Takeshi FujiiDepartment of Pathology, Toranomon Hospital, Tokyo, Japan

Kenichi OhashiDepartment of Pathology, Toranomon Hospital, Tokyo, Japan

Yoshifumi UbaraNephrology Center, Toranomon Hospital, Tokyo, Japan; ;Okinaka Memorial Institute for Medical Research, Tokyo, Japan; Correspondence[email protected]

show all

References

Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10):1879–1885.
PubMed Web of Science ®Google Scholar
Hamanoue S, Suwabe T, Hoshino J, et al. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol. 2016;26(4):610–613.
PubMed Web of Science ®Google Scholar
Koga T, Hagimori N, Sato S, et al. An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance: study protocol for investigator-initiated, multicenter, open-label trial. Medicine (Baltimore). 2020;99(1):e18328.
Web of Science ®Google Scholar
Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54(9):2997–3000.
PubMedGoogle Scholar
Hattori Y, Ubara Y, Sumida K, et al. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid. 2012; 19(1):37–40.
Web of Science ®Google Scholar
Yamada Y, Ueno T, Irifuku T, et al. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: a case report. Clin Nephrol. 2018;90(3):232–236.
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Long term administration of tocilizumab improves renal amyloid A (AA) amyloidosis deposition in Familial Mediterranean fever

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long term administration of tocilizumab improves renal amyloid A (AA) amyloidosis deposition in Familial Mediterranean fever

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date